The Cardiovascular Benefits of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
M. Kallash and W. H. Frishman
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study
C. Xie, P. Iroga, et al.
Three-Dimensional Structural Insights Have Revealed the Distinct Binding Interactions of Agonists, Partial Agonists, and Antagonists with the µ Opioid Receptor
Z. Li, J. Liu, et al.
The benefits and struggles of FAIR data: the case of reusing plant phenotyping data
E. A. Papoutsoglou, I. N. Athanasiadis, et al.
Which kind of board benefits more from the relationship between entrepreneurial orientation and radical innovation? The asymmetric roles of board characteristics in China
Y. Liu, Y. Wu, et al.
